Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer

Reinout H. de Roest,Martijn van der Heijden,Frederik W.R. Wesseling,Emma J. de Ruiter, Martijn W. Heymans,Chris Terhaard,Marije R. Vergeer,Jan Buter,Lot A. Devriese,Jan Paul de Boer,Arash Navran,Ann Hoeben,Conchita Vens,Michiel van den Brekel,Ruud H. Brakenhoff,C. René Leemans,Frank Hoebers

Radiotherapy and Oncology（2022）

引用 0|浏览3

暂无评分

摘要

•Platinum-based CRT for HPV-neg HNSCC has unique treatment course and outcome pattern.•CRT is often too toxic, in ∼35% of patients the cisplatin-dose plan needed changes.•Switching to carboplatin when cisplatin is too toxic seems not beneficial for OS (HR 1.49 vs HR 1.59).•Development of DM was strongly associated with boosting method (SEQ vs SIB; OR 1.91).

查看译文

关键词

HNSCC,Chemoradiotherapy,Cisplatin,HPV-negative,Advanced stage

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要